Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08YQT
|
|||
| Former ID |
DNC000189
|
|||
| Drug Name |
AM251
|
|||
| Synonyms |
AM251; 183232-66-8; AM-251; AM 251; UNII-3I4FA44MAI; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; 3I4FA44MAI; CHEMBL285932; CHEBI:90724; MFCD01861181; CPD000466284; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H21Cl2IN4O
|
|||
| Canonical SMILES |
CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)I
|
|||
| InChI |
1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
|
|||
| InChIKey |
BUZAJRPLUGXRAB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 183232-66-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7427143, 8151442, 11113928, 11120000, 11120488, 11120976, 11121590, 11122070, 11147083, 11362659, 11365221, 11367783, 11370589, 11370590, 11373384, 11375945, 14886159, 24891069, 26719791, 26752081, 26752082, 29221304, 46386990, 47959459, 48334204, 49681171, 49681811, 49689351, 50068054, 50104735, 53790533, 56311975, 57321157, 79751999, 85209665, 85788727, 91746244, 92308639, 92309941, 99300855, 99302373, 103100713, 103209134, 104046577, 104299676, 113635230, 117540808, 124659102, 125334727, 127571931
|
|||
| ChEBI ID |
CHEBI:90724
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3317). | |||
| REF 2 | Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004 Apr;309(1):56-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.